Calidi Biotherapeutics “announced the pricing of its “reasonable best efforts” public offering of 15,197,500 shares of common stock and accompanying Series A Common Warrants, Series B Unit Warrants, with each unit consisting of one share of common stock and a Series B-1 Common Warrant and Series C Unit Warrants, with each unit consisting of one share of common stock and a Series C-1 Common Warrant at an effective combined price of $0.40 per share and common warrants for aggregate gross proceeds of approximately $6.1 million, before deducting placement agent fees and other offering expenses. Ladenburg Thalmann & Co. Inc. is acting as sole placement agent in connection with the offering.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDI:
- Calidi presents new data on mechanism of action for its therapies at AACR
- Calidi price target lowered to $4.50 from $9 at Baird
- Calidi price target lowered to $2 from $11 at H.C. Wainwright
- Calidi Biotherapeutics Issues Regulation FD Disclosure Notice
- Calidi Biotherapeutics Restructures Debt and Streamlines Finances